ANTIBIOTICE S.A.
BVB TICKER: ATB
About the company
With a half a century
of tradition in the field of generic drug manufacturing and a complex portfolio
comprising over 120 medicines covering 11 therapeutic classes, Antibiotice SA is the only producer of injectable cephalosporins and the
main producer of antiinfectives in Romania. In addition, Antibiotice is leader
on the domestic market of the solutions and suspensions for injection filled
into vials in terms of physical units.
The quality of the
company products is attested by the Good Manufacturing Practice (GMP)
Certificate, the Certificate of Suitability to the European Pharmacopoeia and
acceptance by the Food and Drug Administration (FDA) for the US and Canadian
markets.
At present, the company
has 9 production lines, all GMP certified, for the manufacturing of 7 dosage
forms (powders for injectable solutions and suspensions, capsules tablets,
ointments, gels, creams and suppositories) and of the active ingredient
Nystatin.
Company`s portfolio comprises medicines
of human use, of veterinary use, active ingredients and natural fertilizers.
Among the best known brands of medicines made by Antibiotice we can mention:
Moldamin®, Piafen®, Cutaden®, Sinerdol®, Hemorzon®. Sinopryl®,
Ceftriaxon®, Ampiplus®, recommended for a wide range of disorders.
At present, Antibiotice
holds 130 trade marks in the country registered with the Romanian State Office
for Inventions and Trademarks, and 20 international trade marks registered in
over 45 countries worldwide.
History
1955-1959 - In December 1955 came into being the first Romanian
pharmaceutical company. Shortly after, Antibiotice became the first East
European company producing on large scale Alexander Fleming’s famous discovery:
penicillin. Four years later, the streptomycin production facility started
operating and the manufacturing of ointments, creams and suppositories was
initiated.
1960-1977 – The manufacturing lines for active ingredients were
developed (e.g. erythromycin, oxytetracycline, tetracycline, griseofulvin,
sinerdol, lysine). Antibiotice became the only manufacturer of sterile products
for parenteral use (injection) in Romania.
The acceptance of the Streptomycin
manufacturing facility by the Food and Drug Administration (the US regulatory
authority) in 1977 opened the way to the international market.
1977-1989 – In the 80’s, Antibiotice already exported 50% of its
production. Thus, the active ingredients manufactured in Iasi became an
essential element of a wide range of medicines produced both in the country and
worldwide. A number of 44 letters patents in the pharmaceutical field were
registered and 600 technical innovations were implemented in production in the
same period.
1990 – As a result of the changes at macroeconomic level, the
management of the company reoriented the production of pharmaceuticals. The
finished dosage forms gained the main position in the product portfolio, the
active ingredients being manufactured to be used in developing new
pharmaceutical forms. In a short while, the introduction of over 30
pharmaceutical products in manufacture placed the company amongst the top Romanian
manufacturers of anti-infective medicines.
1993-1997 – Major investments exceeding 8 million Euros were carried
out to the purpose of revamping and purchasing state-of-the-art, competitive
equipment. Antibiotice ascends in the top 5 world producers of penicillin and
penicillin derivatives.
1997-2000 – Constantly concerned with the quality of its products,
in 1997 the company started to implement an effective quality assurance system
requiring the strict control of the manufacturing processes. Thus, in 1999,
Antibiotice became the first Romanian producer to obtain the Good Manufacturing
Practice (GMP) Certificate for the facility of powders for injectable
medicines. The ascendant financial evolution resulted in an important
achievement: the company was listed to the Stock Exchange Bucharest.
2000-2004 – The continuous investments in research, people training,
and quality as well as in updating the production lines and working areas
turned Antibiotice into a profitable, dynamic company with a healthy economic
growth.
2005 – Upon celebrating 50 years of activity, Antibiotice
launched a new corporate brand identity. Starting with December, the company
had a new logo and a new slogan which reflect the massive transformations
undergone by the company in terms of organizational structure, technology, and
culture.
January 2006 – LLOYD’S REGISTER QUALITY ASSURANCE granted Antibiotice
the ISO 9001:2000 certificate for the Quality Management System in the field of
pharmaceutical product manufacturing.
Major shareholders
|
Shareholder |
Shares |
Percent |
|
A.V.A.S. |
241,174,148 |
53.02% |
|
OTHER SHAREHOLDERS |
144,849,455 |
31.84% |
|
S.I.F. OLTENIA |
45,923,746 |
10.10% |
|
NON-RESIDENT CLIENTS-CITIBANK |
22,949,942 |
5.05% |
|
Total No. of Shares |
454,897,291 |
|
Nominal Value |
0.1000 |
|
Share Capital |
45,489,729.10 |
Annual financial information (Key financials)
|
|
2006(RON) |
2005(RON) |
2004(RON)* |
|
Fixed assets - Total |
106,793,221.00 |
85,596,263.00 |
80,982,640.00 |
|
Current assets - Total |
153,595,074.00 |
126,159,137.00 |
107,946,721.20 |
|
|
|
|
|
|
Debtors - due within one year |
68,662,036.00 |
54,405,204.00 |
58,483,297.10 |
|
Current assets/Net current liabilities |
85,181,691.00 |
71,819,222.00 |
49,667,259.00 |
|
Total assets less current liabilities |
183,101,563.00 |
149,006,512.00 |
122,993,261.20 |
|
Debtors - due after more than one year |
2,547,890.00 |
1,825,211.00 |
4,434,342.80 |
|
Revenues in advance |
8,873,349.00 |
8,409,022.00 |
7,660,604.40 |
|
|
|
|
|
|
Subscribed paid up capital |
45,489,729.00 |
45,489,729.00 |
40,435,314.80 |
|
Shareholders equity - Total |
177,059,654.00 |
143,580,488.00 |
117,358,918.40 |
|
|
|
|
|
|
Total receivables |
106,591,713.00 |
98,496,131.00 |
82,976,615.30 |
|
Total liabilities |
71,209,926.00 |
56,230,415.00 |
62,917,639.90 |
|
|
|
|
|
|
Net turnover |
195,677,945.00 |
163,497,747.00 |
136,028,514.50 |
|
|
|
|
|
|
Operating income - Total |
193,392,713.00 |
164,867,029.00 |
139,796,503.60 |
|
Operating expenses - Total |
164,311,849.00 |
138,522,664.00 |
122,903,619.80 |
|
Operating result |
29,080,864.00 |
26,344,365.00 |
16,892,883.80 |
|
|
|
|
|
|
Financial income - Total |
4,355,603.00 |
1,652,932.00 |
3,536,033.90 |
|
Financial expenses - Total |
3,362,907.00 |
4,272,442.00 |
2,851,956.40 |
|
Financial result |
992,696.00 |
-2,619,510.00 |
684,077.50 |
|
Current result |
30,073,560.00 |
23,724,855.00 |
17,576,961.30 |
|
|
|
|
|
|
Extraordinary income |
0.00 |
0.00 |
0.00 |
|
Extraordinary expenses |
0.00 |
0.00 |
0.00 |
|
Extraordinary result |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
Total revenues |
197,748,316.00 |
166,519,961.00 |
143,332,537.50 |
|
Total expenses |
167,674,756.00 |
142,795,106.00 |
125,755,576.20 |
|
|
|
|
|
|
Gross result |
30,073,560.00 |
23,724,855.00 |
17,576,961.30 |
|
Net result |
23,839,146.00 |
19,678,661.00 |
12,424,687.00 |
|
Result per share |
- |
- |
0.0307 |
|
|
|
|
|
|
Back payments - Total |
14,350,243.00 |
15,465,882.00 |
8,929,856.90 |
|
Back payments for suppliers - Total |
11,338,449.00 |
12,533,610.00 |
6,778,473.10 |
|
Back payments of liabilities to the social insurance budget
|
0.00 |
0.00 |
0.00 |
|
Taxes which are not paid to the State budget upon payment
date |
0.00 |
0.00 |
0.00 |
|
|
|
|
|
|
Average number of employees (only full time employees)
|
1556 |
1650 |
1753 |
|
|
|
|
|